0H22.LSE Bioinvent International AB

Healthcare Commercial Services & Supplies London Exchange
- SEK
Market cap
-
P/E
-
P/B
-
ROE
-108.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.

Is 0H22.LSE undervalued?

Graham number

The Graham number of Bioinvent International AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bioinvent International AB fundamental analysis

No fundamental analysis for Bioinvent International AB yet.

Bioinvent International AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bioinvent International AB

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tu…

Full company profile